0001213900-24-024305.txt : 20240320 0001213900-24-024305.hdr.sgml : 20240320 20240320134406 ACCESSION NUMBER: 0001213900-24-024305 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240319 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240320 DATE AS OF CHANGE: 20240320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 24767300 BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 8-K 1 ea0202208-8k_inmed.htm CURRENT REPORT
false 0001728328 A1 BC 0001728328 2024-03-19 2024-03-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 19, 2024

 

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

 

British Columbia   001-39685   98-1428279
(State or Other Jurisdiction
of Incorporation) 
  (Commission File Number)    (IRS Employer
Identification No.) 

 

InMed Pharmaceuticals Inc.

Suite 310 - 815 W. Hastings Street,

Vancouver, B.C.

Canada 

  V6C 1B4
(Address of Principal Executive Offices)   (Zip Code)

 

Company’s telephone number, including area code: (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)    Name of each exchange
on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

As previously reported by InMed Pharmaceuticals Inc. (the “Company”) on its Current Report on Form 8-K, the Company received a notification letter, dated September 19, 2023, from the Nasdaq Stock Market, LLC (“Nasdaq”), indicating that, based on the previous 30 consecutive business days, the Company’s listed shares (the “Listed Shares”) no longer met the minimum $1.00 bid price per share requirement for the continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). Therefore, in accordance with the Nasdaq Listing Rules, the Company was provided 180 calendar days, or until March 18, 2024, to regain compliance with such requirement.

 

On March 19, 2024, the Company received written notification (the “Current Notification”) from the Listing Qualifications Department of Nasdaq that the Company has been granted an additional 180-day compliance period, or until September 16, 2024 (the “Extended Compliance Period”), to regain compliance with the Minimum Bid Price Rule. Nasdaq’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company’s written notice of its intention to consider all available options to regain compliance during the Extended Compliance Period, including, if necessary, effecting a reverse stock split.

 

If at any time prior to September 16, 2024, the closing bid price of the Listed Shares is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with the Minimum Bid Price Rule and this matter will be closed. If the Company does not regain compliance with the Minimum Bid Price Rule during the Extended Compliance Period, Nasdaq will provide written notification to the Company that the Listed Shares will be delisted. At that time, the Company may appeal the relevant delisting determination to a hearings panel (the “Hearings Panel”) pursuant to the procedures set forth in the Nasdaq Listing Rules. However, if the Company does appeal Nasdaq’s delisting determination to the Hearings Panel, there can be no assurance that such appeal would be successful.

 

The Current Notification has no immediate effect on the listing or trading of the Listed Shares, which will continue to trade on the Nasdaq Capital Market under the symbol “INM.”

 

Item 7.01 Regulation FD Disclosure.

 

On March 20, 2024, the Company issued a press release announcing its receipt of the 180-day extension from Nasdaq to regain compliance with the Minimum Bid Price Rule. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

The following exhibits shall be deemed to be furnished, and not filed:

 

Exhibit No.   Description
99.1   News release, dated March 20, 2024 
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMED PHARMACEUTICALS INC.
     
Date: March 20, 2024 By: /s/ Eric A Adams
    Eric A. Adams
    President & CEO

 

 

2

 

 

 

EX-99.1 2 ea020220801ex99-1_inmed.htm NEWS RELEASE, DATED MARCH 20, 2024

Exhibit 99.1

 

NASDAQ: INM

 

Suite 310-815 W. Hastings St.

Vancouver, BC, Canada V6C 1B4

Tel: +1.604.669.7207

Email: info@inmedpharma.com

www.inmedpharma.com

 

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

 

Vancouver, BC – March 20, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced that it has received a notification letter from the Listing Qualifications Department of Nasdaq Stock Market LLC (“Nasdaq”) that the Company has been granted an additional 180-day compliance period, or until September 16, 2024 (the “Extended Compliance Period”), to regain compliance with Nasdaq’s minimum bid price requirement for the continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”).

 

Nasdaq’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company’s written notice of its intention to consider all available options to regain compliance during the Extended Compliance Period, including, if necessary, effecting a reverse stock split.

 

If at any time prior to September 16, 2024, the closing bid price of the Company’s ordinary shares is at least $1.00 per share for at least a minimum of 10 consecutive business days, the Company will regain compliance with the Minimum Bid Price Rule and this matter will be closed.

 

As previously reported, in a notification letter dated September 19, 2023, Nasdaq had informed the Company that, based on the previous 30 consecutive business days, the Company’s ordinary shares no longer met the minimum $1.00 bid price per share requirement as set forth in the Minimum Bid Price Rule. Therefore, in accordance with the Nasdaq Listing Rules, the Company was provided 180 calendar days, or until March 18, 2024, to regain compliance with such requirement.

 

This current notification from Nasdaq has no immediate effect on the listing or trading of the Company’s ordinary shares, which will continue to trade on the Nasdaq Capital Market under the symbol “INM.”

 

About InMed:

 

InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. Together with our subsidiary, BayMedica LLC, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. We are a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.

 

Investor Contact:

 

Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1 604 416 0999

E: cclancy@inmedpharma.com

 

 

 

 

Cautionary Note Regarding Forward-Looking Information:

 

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and other applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. This news release contains forward-looking statements, including, but not limited to, statements regarding the Company’s ability to regain compliance with the Minimum Bid Price Rule, the Company’s intention to monitor closing bid prices of its ordinary shares and the Company’s plans to consider implementing available options to regain compliance with the Minimum Bid Price Rule, including, if necessary, effecting a reverse stock split. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of known and unknown risks and uncertainties, including the risk that (i) the Company may not otherwise meet the requirements for continued listing under the Nasdaq Listing Rules, (ii) the Company may not meet the Minimum Bid Price Rule during the Extended Compliance Period or any other compliance period in the future, (iii) Nasdaq may not grant the Company relief from delisting, if necessary, and (iv) the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary, among other risks and uncertainties.

 

Beyond the foregoing, there are additional known and unknown risk factors and uncertainties, any of which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A further discussion of these risks and uncertainties facing InMed’s stand-alone business is contained in InMed’s most recent Annual Report on Form 10-K and other filings the Company makes with the Securities and Exchange Commission from time to time on www.sec.gov.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by applicable law.

 

 

 

 

GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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inm-20240319.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 inm-20240319_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 inm-20240319_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Mar. 19, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 19, 2024
Entity File Number 001-39685
Entity Registrant Name INMED PHARMACEUTICALS INC.
Entity Central Index Key 0001728328
Entity Tax Identification Number 98-1428279
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 310 - 815 W. Hastings Street
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V6C 1B4
City Area Code 604
Local Phone Number 669-7207
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol INM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, dei:EntityIncorporationStateCountryCode - ea0202208-8k_inmed.htm 21, 22 ea0202208-8k_inmed.htm inm-20240319.xsd inm-20240319_lab.xml inm-20240319_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0202208-8k_inmed.htm": { "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20240319", "dts": { "inline": { "local": [ "ea0202208-8k_inmed.htm" ] }, "schema": { "local": [ "inm-20240319.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "inm-20240319_lab.xml" ] }, "presentationLink": { "local": [ "inm-20240319_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://inmedpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0202208-8k_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0202208-8k_inmed.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001213900-24-024305-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-024305-xbrl.zip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ea0202208-8k_inmed_htm.xml IDEA: XBRL DOCUMENT 0001728328 2024-03-19 2024-03-19 iso4217:USD shares iso4217:USD shares false 0001728328 A1 BC 8-K 2024-03-19 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 Suite 310 - 815 W. Hastings Street Vancouver CA V6C 1B4 604 669-7207 false false false false Common Shares, no par value INM NASDAQ true false